
Pieter J Visser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1441385/publications.pdf Version: 2024-02-01



DIFTED I VISSED

#	Article	IF	CITATIONS
1	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
2	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.4	24
3	Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer's disease. World Journal of Biological Psychiatry, 2022, 23, 264-277.	1.3	8
4	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
5	Genetically identical twins show comparable tau PET load and spatial distribution. Brain, 2022, 145, 3571-3581.	3.7	12
6	CSF proteomic signature predicts progression to Alzheimer's disease dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12240.	1.8	3
7	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	4.1	9
8	Spatial-Temporal Patterns of \hat{l}^2 -Amyloid Accumulation. Neurology, 2022, 98, .	1.5	40
9	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, 27.	4.4	30
10	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	1.7	20
11	Assessment of Social Behavior Using a Passive Monitoring App in Cognitively Normal and Cognitively Impaired Older Adults: Observational Study. JMIR Aging, 2022, 5, e33856.	1.4	2
12	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
13	Effects of age, amyloid, sex, and <i>APOE</i> Îμ4 on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	1.2	4
14	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers. Clinical Proteomics, 2022, 19, 13.	1.1	10
15	Regional associations of white matter hyperintensities and early cortical amyloid pathology. Brain Communications, 2022, 4, .	1.5	9
16	Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's Aβ amyloidosis. Acta Neuropathologica Communications, 2022, 10, .	2.4	8
17	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. Alzheimer's Research and Therapy, 2022, 14, .	3.0	5
18	Longitudinal retinal layer changes in preclinical Alzheimer's disease. Acta Ophthalmologica, 2021, 99, 538-544.	0.6	13

#	Article	IF	CITATIONS
19	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 1499-1511.	2.4	14
20	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.0	24
21	36â€month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 29-40.	0.4	77
22	General practitioners' attitude toward early and preâ€dementia diagnosis of AD in five European countries—A MOPEAD project survey. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12130.	1.2	10
23	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. Alzheimer's Research and Therapy, 2021, 13, 2.	3.0	18
24	Amyloidâ€ <i>β</i> , cortical thickness, and subsequent cognitive decline in cognitively normal oldestâ€old. Annals of Clinical and Translational Neurology, 2021, 8, 348-358.	1.7	9
25	White matter microstructure disruption in early stage amyloid pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12124.	1.2	16
26	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12216.	1.2	7
27	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
28	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Annals of Neurology, 2021, 89, 987-1000.	2.8	20
29	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 64.	3.0	6
30	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimer's Research and Therapy, 2021, 13, 89.	3.0	28
31	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.4	44
32	Identification of undiagnosed dementia cases using a webâ€based preâ€screening tool: The MOPEAD project. Alzheimer's and Dementia, 2021, 17, 1307-1316.	0.4	8
33	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology, 2021, 96, e2673-e2684.	1.5	37
34	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.4	23
35	Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	3.0	19
36	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	1.7	16

#	Article	IF	CITATIONS
37	Complementary preâ€screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project. Alzheimer's and Dementia, 2021, , .	0.4	3
38	Genetic overlap between Alzheimer's disease and blood lipid levels. Neurobiology of Aging, 2021, 108, 189-195.	1.5	5
39	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	1.7	9
40	A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer's Disease: Results from the MOPEAD Project. Journal of Alzheimer's Disease, 2021, 83, 1149-1159.	1.2	4
41	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications, 2021, 3, fcab201.	1.5	14
42	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Translational Psychiatry, 2021, 11, 451.	2.4	6
43	Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42. Neurobiology of Aging, 2021, 107, 42-52.	1.5	2
44	A methodology for cohort harmonisation in multicentre clinical research. Informatics in Medicine Unlocked, 2021, 27, 100760.	1.9	9
45	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	1.4	7
46	Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Scientific Reports, 2021, 11, 22675.	1.6	27
47	Magnetoencephalography Brain Signatures Relate to Cognition and Cognitive Reserve in the Oldest-Old: The EMIF-AD 90 + Study. Frontiers in Aging Neuroscience, 2021, 13, 746373.	1.7	5
48	Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis. Scientific Data, 2021, 8, 312.	2.4	12
49	Social behavior assessment in cognitively impaired older adults using a passive and remote smartphone application. Alzheimer's and Dementia, 2021, 17, e051698.	0.4	1
50	Decorin is an early CSF biomarker of Alzheimer's Aβ amyloidosis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
51	Associations between CSF proteins and medial temporal lobe atrophy across the AD continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	0
52	The association between diabetes and Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
53	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
54	Amyloid discordance analysis in cognitively normal monozygotic twins demonstrates that the memory domain is affected first in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
55	Is A+T―Alzheimer's disease or not? A combined CSF and pathology study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
56	Updated prevalence estimates of amyloid positivity from cognitively normal to clinical Alzheimer's disease dementia: The Amyloid Biomarker Study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
57	Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. Alzheimer's and Dementia, 2021, 17, .	0.4	3
58	Associations of lifestyle factors with amyloid positivity in cognitively normal individuals at different levels of genetic risk: The amyloid biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
59	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
60	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [¹⁸ F]flortaucipir PET study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
61	An app to measure functional decline in managing finances in Alzheimer's disease: Preliminary results of the RADARâ€AD study. Alzheimer's and Dementia, 2021, 17, .	0.4	2
62	Dataâ€driven evidence for three distinct patterns of amyloidâ€Î² accumulation. Alzheimer's and Dementia, 2021, 17, .	0.4	2
63	Alzheimer's disease genetic risk variants show brain cell typeâ€specific associations with protein levels in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, e049531.	0.4	0
64	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
65	Plasma Pâ€ŧau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years. Alzheimer's and Dementia, 2021, 17, .	0.4	0
66	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0
67	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
68	Augmented reality to detect subtle alterations in the early stages of Alzheimer's disease: Preliminary results of the RADARâ€AD study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
69	Gait characteristics in preclinical Alzheimer's disease: Preliminary results of the RADARâ€AD study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
70	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. Alzheimer's and Dementia, 2021, 17, e053030.	0.4	0
71	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451.	0.4	0
72	Optical coherence tomography angiography in preclinical Alzheimer's disease. British Journal of Ophthalmology, 2020, 104, 157-161.	2.1	95

#	Article	IF	CITATIONS
73	Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a systematic review and meta-analysis. Brain Imaging and Behavior, 2020, 14, 2799-2816.	1.1	36
74	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60–102 Years. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1609-1617.	1.7	7
75	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 86-98.	2.7	40
76	Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 256-264.	1.2	6
77	Heritability estimates for 361 blood metabolites across 40 genome-wide association studies. Nature Communications, 2020, 11, 39.	5.8	64
78	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	3.0	12
79	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	1.5	11
80	Realâ€world evidence in Alzheimer's disease: The ROADMAP Data Cube. Alzheimer's and Dementia, 2020, 16, 461-471.	0.4	13
81	Microvascular changes of the retina in ankylosing spondylitis, and the association with cardiovascular disease – the eye for a heart study. Seminars in Arthritis and Rheumatism, 2020, 50, 1535-1541.	1.6	3
82	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Communications, 2020, 2, fcaa102.	1.5	11
83	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.5	55
84	A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data. Translational Psychiatry, 2020, 10, 211.	2.4	27
85	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	2.4	42
86	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
87	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Alzheimer's and Dementia, 2020, 16, e037184.	0.4	2
88	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. Alzheimer's and Dementia, 2020, 16, e037912.	0.4	0
89	CSF proteomic changes in preâ€preclinical Alzheimer's disease: A monozygotic twin study. Alzheimer's and Dementia, 2020, 16, e038966.	0.4	0
90	The impact of a nutritional intervention in prodromal Alzheimer's disease: The LipiDiDiet clinical trial. Alzheimer's and Dementia, 2020, 16, e039846.	0.4	0

#	Article	IF	CITATIONS
91	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.4	0
92	Amygdalar nuclei and hippocampal subfields on MRI: Testâ€retest reliability of automated segmentation in old and young healthy volunteers. Alzheimer's and Dementia, 2020, 16, e040322.	0.4	0
93	General practitioners' opinion on early and preâ€dementia diagnosis of AD: A MOPEAD project survey in five European countries. Alzheimer's and Dementia, 2020, 16, e040357.	0.4	Ο
94	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e040774.	0.4	0
95	Amyloidâ€Î² deposition in cognitively normal oldestâ€old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e040991.	0.4	Ο
96	Research diagnostic criteria for Alzheimer's disease: Findings from the multinational LipiDiDiet Trial. Alzheimer's and Dementia, 2020, 16, e042530.	0.4	0
97	Predictors of preclinical Alzheimer's disease in persons with subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e042658.	0.4	1
98	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e042739.	0.4	0
99	Amyloidâ€Î² deposition in cognitively normal oldestâ€old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e042768.	0.4	Ο
100	The IMIâ€EU H2020 project MOPEAD: Outcome of different screening methods to identify MCI/early AD. Alzheimer's and Dementia, 2020, 16, e044524.	0.4	1
101	Amyloidâ€dependent association of grey matter network disruptions with phosphoâ€ŧau in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044739.	0.4	Ο
102	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.4	1
103	Preâ€screening models for patient engagement: The MOPEAD project. Alzheimer's and Dementia, 2020, 16, e044796.	0.4	1
104	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. Alzheimer's and Dementia, 2020, 16, e045112.	0.4	0
105	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in nonâ€demented memory clinic participants. Alzheimer's and Dementia, 2020, 16, e045196.	0.4	Ο
106	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. Alzheimer's and Dementia, 2020, 16, e045230.	0.4	1
107	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. Alzheimer's and Dementia, 2020, 16, e045470.	0.4	0
108	Plasma amyloidâ€Î² oligomerization assay as a screening test for abnormal amyloid status. Alzheimer's and Dementia, 2020, 16, e045754.	0.4	0

#	Article	IF	CITATIONS
109	DNA methylation differences associated with peripheral biomarkers in the EMIFâ€AD cohort. Alzheimer's and Dementia, 2020, 16, e045853.	0.4	0
110	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. Alzheimer's and Dementia, 2020, 16, e045876.	0.4	0
111	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. Alzheimer's and Dementia, 2020, 16, e046102.	0.4	Ο
112	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	3.0	14
113	Ocular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study. BMC Geriatrics, 2020, 20, 155.	1.1	8
114	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
115	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. NeuroImage, 2020, 218, 116932.	2.1	38
116	APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 65.	3.0	28
117	ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, e46-e58.	1.5	97
118	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. Neurobiology of Aging, 2020, 93, 144.e1-144.e15.	1.5	7
119	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	1.2	13
120	Duration of Care Trajectories in Persons With Dementia Differs According to Demographic and Clinical Characteristics. Journal of the American Medical Directors Association, 2020, 21, 1102-1107.e6.	1.2	8
121	The European medical information framework: A novel ecosystem for sharing healthcare data across Europe. Learning Health Systems, 2020, 4, e10214.	1.1	20
122	Time from diagnosis to institutionalization and death in people with dementia. Alzheimer's and Dementia, 2020, 16, 662-671.	0.4	44
123	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	2.5	45
124	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.4	29
125	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
126	Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case–control study using European electronic health records. BMJ Open, 2020, 10, e038753.	0.8	12

#	Article	IF	CITATIONS
127	AB0728â€MICROVASCULAR CHANGES OF THE RETINA IN ANKYLOSING SPONDYLITIS, AND THE ASSOCIATION WITH CARDIOVASCULAR DISEASE – THE EYE FOR A HEART STUDY Annals of the Rheumatic Diseases, 2020, 79, 1658.2-1659.	0.5	0
128	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	1.2	18
129	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 1149-1159.	0.4	45
130	Retinal thickness as a potential biomarker in patients with amyloidâ€proven early―and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 463-471.	1.2	25
131	Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project. Journal of Alzheimer's Disease, 2019, 67, 495-501.	1.2	24
132	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research and Therapy, 2019, 11, 74.	3.0	28
133	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
134	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
135	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
136	White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. Journal of the American Geriatrics Society, 2019, 67, 1827-1834.	1.3	28
137	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.4	290
138	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
139	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology, 2019, 92, e2699-e2705.	1.5	10
140	The association of vascular disorders with incident dementia in different age groups. Alzheimer's Research and Therapy, 2019, 11, 47.	3.0	19
141	Retinal layer thickness in preclinical Alzheimer's disease. Acta Ophthalmologica, 2019, 97, 798-804.	0.6	36
142	The MOPEAD project: Advancing patient engagement for the detection of "hidden―undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
143	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.4	134
144	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101786.	1.4	27

#	Article	IF	CITATIONS
145	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
146	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.4	82
147	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	1.2	8
148	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiology of Aging, 2019, 77, 58-65.	1.5	14
149	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.4	0
150	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€ŧype dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70
151	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM Alzheimer's and Dementia, 2019, 15, P24.</i>	0.4	0
152	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 2019, 11, 94.	3.0	20
153	Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	1.2	23
154	Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.4	232
155	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 1-9.	1.2	14
156	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	1.2	34
157	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ¹⁸ F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. Journal of Nuclear Medicine, 2019, 60, 541-547.	2.8	47
158	ALZHEIMER'S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL PRODROMAL ALZHEIMER'S DISEASE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	IN 1.5	10
159	White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiology of Aging, 2018, 66, 40-48.	1.5	20
160	Capturing the Alzheimer's disease pathological cascade. Lancet Neurology, The, 2018, 17, 199-200.	4.9	4
161	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.4	20
162	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58

#	Article	IF	CITATIONS
163	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
164	Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiology of Aging, 2018, 61, 138-145.	1.5	32
165	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
166	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1–42 Analysis Results. Clinical Chemistry, 2018, 64, 576-585.	1.5	126
167	Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimer's and Dementia, 2018, 14, 130-139.	0.4	44
168	P3â€216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOG OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIFâ€AD 90+ STUDY. Alzheimer's and Dementia, 2018, 14, P1153.	Y 0.4	0
169	P3â€368: PREDICTING AND MONITORING SHORTâ€TERM DISEASE PROGRESSION IN Aâ€MCI PATIENTS WITH PRODROMAL AD USING MRI STRUCTURAL BRAIN BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P1230.	0.4	0
170	P4â€158: THE ASSOCIATION OF VASCULAR DISORDERS WITH INCIDENT DEMENTIA AND MORTALITY IN DIFFERENT AGE GROUPS IN A PRIMARY CARE DATABASE. Alzheimer's and Dementia, 2018, 14, P1499.	0.4	1
171	P2â€270: INCREASED CSF AMYLOIDâ€Î² 1â€38 AND 1â€40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COG IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P780.	NITIVE 0.4	0
172	ICâ€₽â€066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDER IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P59.	2LY 0.4	0
173	ICâ€Pâ€182: EVENTâ€BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL βâ€AMYLOID DEPOSITION BRAIN. Alzheimer's and Dementia, 2018, 14, P152.	N IN THE	1
174	P3â€233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.4	0
175	O1â€13â€01: ROLE OF THE INFLAMMASOME COMPLEX IN ADâ€RELATED HIPPOCAMPAL NEURODEGENERATION PATIENTS WITH AD PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P251.	I IN MCI 0.4	0
176	P1â€418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P465.	0.4	0
177	P1â€525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2018, 14, P533.	0.4	0
178	ICâ€₽â€126: VOLUMETRIC ACCURACY OF A FULLY AUTOMATIC TOOL FOR WHITE MATTER HYPERINTENSITIES (WMHS) SEGMENTATION. Alzheimer's and Dementia, 2018, 14, P105.	0.4	1
179	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVER' STUDY. Alzheimer's and Dementia, 2018, 14, P204.	Y 0.4	0
180	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE O BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, P1176.	F 0.4	0

#	Article	IF	CITATIONS
181	O2â€09â€06: FREQUENCIES OF CEREBROSPINAL FLUID A/T/N BIOMARKER PROFILES AND THEIR ASSOCIATION WITH MEMORY FUNCTION IN PERSONS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2018, 14, P643.	0.4	0
182	O2â€09â€05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES. Alzheimer's and Dementia, 2018, 14, P643.	0.4	0
183	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.4	0
184	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.4	0
185	ICâ€Pâ€005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRO EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P16.	N 0.4	0
186	P3â€585: COGNITIVE RESERVE MODULATES THE ASSOCIATION OF CEREBRAL AMYLOID PATHOLOGY WITH COGNITIVE PERFORMANCE IN PERSONS WITH ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1349.	0.4	0
187	P2â€445: EVENTâ€BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL βâ€AMYLOID DEPOSITION IN BRAIN. Alzheimer's and Dementia, 2018, 14, P887.	THE 0.4	1
188	P3â€568: PROGNOSIS OF INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT REVERTING TO NORMAL COGNITION Alzheimer's and Dementia, 2018, 14, P1341.	^V 0.4	0
189	F1â€02â€02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATIN TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.	G 0.4	0
190	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatrics, 2018, 18, 289.	1.1	25
191	P3â€355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P1221.	0.4	0
192	P1â€247: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AS A DIFFERENTIAL DIAGNOSIS BIOMARKER IN NEUROLOGICAL DISEASES: A SYSTEMATIC REVIEW AND METAANALYSIS. Alzheimer's and Dementia, 2018, 14, P373.	N 0.4	1
193	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	1.7	28
194	F1â€02â€01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENTâ€LIGHT AND YKLâ€40 TO Aβ, APOE ε4 COGNITION: RESULTS FROM THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P201.	AND 0.4	0
195	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
196	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	3.0	64
197	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	3.0	46
198	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.4	0

#	Article	IF	CITATIONS
199	F1â€02â€03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVEI STUDY. Alzheimer's and Dementia, 2018, 14, P202.	^{γγ} 0.4	0
200	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	3.7	102
201	Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. , 2018, 59, 5025.		15
202	P4â€077: BLOOD INFLAMMATORY PROFILES MEASURED BY THE ADFLAG [®] TEST ENABLE STRATIFICATION OF PREâ€ÐEMENTIA ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1464.	0.4	0
203	The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research and Therapy, 2018, 10, 75.	3.0	48
204	Chasing the start of sporadic Alzheimer's disease running in families. Brain, 2018, 141, 1589-1591.	3.7	2
205	Preâ€amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology, 2018, 5, 1037-1047.	1.7	23
206	Personality and Dementia. , 2018, , 83-110.		0
207	Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Frontiers in Aging Neuroscience, 2018, 10, 193.	1.7	16
208	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	3.0	62
209	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67.	1.7	29
210	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. Journal of Psychiatric Research, 2018, 104, 183-191.	1.5	21
211	Age dependency of risk factors for cognitive decline. BMC Geriatrics, 2018, 18, 187.	1.1	85
212	Preclinical Alzheimer's Disease: Implications for Refinement of the Concept. Journal of Alzheimer's Disease, 2018, 64, S213-S227.	1.2	8
213	Early-Onset Dementia. Alzheimer Disease and Associated Disorders, 2017, 31, 146-151.	0.6	12
214	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
215	Retinal thickness in Alzheimer's disease: A systematic review andÂmetaâ€analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 162-170.	1.2	152
216	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.4	32

#	Article	IF	CITATIONS
217	Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population. Alzheimer's Research and Therapy, 2017, 9, 8.	3.0	60
218	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	1.5	59
219	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimer's Research and Therapy, 2017, 9, 27.	3.0	66
220	Modifiable Risk Factors for Prevention ofÂDementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index. Journal of Alzheimer's Disease, 2017, 58, 537-547.	1.2	95
221	Brain Amyloid Pathology and Cognitive Function. JAMA - Journal of the American Medical Association, 2017, 317, 2285.	3.8	15
222	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
223	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
224	Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. Ageing Research Reviews, 2017, 36, 42-49.	5.0	10
225	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	1.5	60
226	Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects. Annals of Neurology, 2017, 81, 749-753.	2.8	20
227	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
228	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
229	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	1.2	33
230	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 965-975.	4.9	175
231	Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2017, 60, 1477-1487.	1.2	31
232	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	1.2	27
233	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1387-1395.	1.2	24
234	Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs. Scientific Reports, 2017, 7, 9685.	1.6	38

#	Article	IF	CITATIONS
235	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 513-523.	1.8	17
236	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
237	[P2–399]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P783.	0.4	0
238	[P3–062]: ACROSS‧ESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI‧ITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P954.	0.4	0
239	[P3–214]: ADFLAG [®] , A DIAGNOSTIC BLOOD TEST FOR PREâ€DEMENTIA STAGES OF ALZHEIMER' DISEASE. Alzheimer's and Dementia, 2017, 13, P1019.	^S 0.4	0
240	[P4–157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.4	4
241	[P4–226]: BEST COMBINATORIAL LOW OST MARKERS TO PREDICT MCI CONVERSION: AN EMIFâ€AD FEDERATION STUDY. Alzheimer's and Dementia, 2017, 13, P1356.	0.4	0
242	[ICâ€Pâ€036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.	0.4	0
243	[ICâ€Pâ€053]: EARLY ALTERATIONS IN RESTINGâ€6TATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMY PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P43.	LOID 0.4	0
244	[ICâ€Pâ€058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
245	[ICâ€Pâ€065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P53.	0.4	0
246	[ICâ€Pâ€167]: ACROSSâ€SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTIâ€SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P126.	0.4	0
247	[P1–250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.4	0
248	[P1–289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOIDâ€PET) IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.		0
249	[P1–387]: CHARACTERIZATION OF SUSPECTED NONâ€ALZHEIMER's DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING. Alzheimer's and Dementia, 2017, 13, P414.	0.4	0
250	[P1–404]: EARLY ALTERATIONS IN RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLO PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P429.)ID 0.4	0
251	[P1–411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDER MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P433.	-Y 0.4	0
252	[P1–575]: PREVALENCE OF THE APOLIPOPROTEIN E ε4 ALLELE IN AMYLOIDâ€Î² POSITIVE SUBJECTS ACROSS T SPECTRUM OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P515.	:НЕ 0.4	0

#	Article	IF	CITATIONS
253	[P2–212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIFâ€AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.4	1
254	[F1–04–02]: EPAD REGISTRY. Alzheimer's and Dementia, 2017, 13, P178.	0.4	0
255	[F1–04–04]: EUROPEAN MEDICAL FRAMEWORK FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 201 13, P178.	7 _{0.4}	0
256	[O1–05–03]: CSF AMYLOID BETA 1–42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€ÐEPENU UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	DENT 0.4	0
257	[O2–05–01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.	0.4	Ο
258	[O2–12–03]: DURATION OF ALZHEIMER's DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAG MULTI TATE MODEL ANALYSIS. Alzheimer's and Dementia, 2017, 13, P585.	E: A 0.4	4
259	[O3–06–03]: THE IMPACT OF AMYLOID AND TAU PATHOLOGY ON THE DEVELOPMENT OF SUBTLE COGNITIN CHANGES IN PERSONS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2017, 13, P912.	/E 0.4	0
260	[P2–194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€ALZHEIMER's DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P680.	0.4	0
261	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease, 2017, 60, 201-210.	1.2	11
262	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 73.	3.0	25
263	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	3.0	43
264	Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 26-35.	1.2	58
265	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a â€̃European <scp>ADNI</scp> study'. Journal of Internal Medicine, 2016, 279, 576-591.	2.7	64
266	Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. Journal of Alzheimer's Disease, 2016, 52, 875-885.	1.2	8
267	P3-031: EPAD Register: A Novel Tool for Pre-Screening Participants in the IMI European Prevention of Alzheimer's Dementia Project (EPAD). , 2016, 12, P828-P829.		0
268	P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.4	0
269	O3-05-03: Modifiable Risk Factors for Prevention of Dementia in Midlife and Late Life: The Libra Index. , 2016, 12, P295-P296.		2
270	ICâ€Pâ€017: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P23.	0.4	0

#	Article	IF	CITATIONS
271	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P7-P8.		0
272	P1â€264: Structural and Diffusion Tensor Imaging in MCI Subjects With Intermediate Risk of Alzheimer's Disease Based on CSF Profile. Alzheimer's and Dementia, 2016, 12, P514.	0.4	0
273	P1-366: Subjective Versus Objective Cognitive Decline in Memory Clinic Visitors. , 2016, 12, P571-P571.		0
274	P2-165: Resilience to Clinical Dementia at Old Age: The European Medical Information Framework (EMIF) 90+ Study. , 2016, 12, P678-P678.		0
275	P2-237: Concordance of [18F] Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P714-P715.		0
276	ICâ€Pâ€120: Association Between Brain MRI Diffusion Alterations and CSF Biomarkers in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P89.	0.4	2
277	ICâ€Pâ€122: Structural and Diffusion Tensor Imaging in MCI Subjects With Intermediate Risk of Alzheimer's Disease Based on CSF Profile. Alzheimer's and Dementia, 2016, 12, P90.	0.4	0
278	ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.4	0
279	ICâ€Pâ€148: Association Between Volumes Alterations and CSF Biomarkers in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P110.	0.4	0
280	P3â€⊋32: Association Between Brain MRI Diffusion Alterations and CSF Biomarkers in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P914.	0.4	0
281	P3â€269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P935.	0.4	0
282	P3â€315: Differential Effects of Apoe and CSF Amyloid on Memory Impairment in Individuals with Amnestic MCI Using the Cantab Cognitive Battery: Results from the Europeanâ€Adni Study. Alzheimer's and Dementia, 2016, 12, P964.	0.4	1
283	P4â€112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.4	0
284	P4â€146: Largeâ€Vessel Disease and [18F]Flutemetamolâ€Amyloid Deposition in Cognitively Healthy Elderly Twins. Alzheimer's and Dementia, 2016, 12, P1069.	0.4	0
285	P4â€153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.4	1
286	P4-165: Association Between Volume Alterations and CSF Biomarkers in Amnestic MCI. , 2016, 12, P1080-P1080.		0
287	P4â€⊋24: Alzheimer's Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, P1115.	0.4	3
288	O1-11-03: Prevalence of Amyloid-b Pathology in Primary Progressive Aphasia Variants: A Multicenter Study. , 2016, 12, P202-P203.		0

17

#	Article	IF	CITATIONS
289	O2â€04â€01: Cognitive Composite Measures in Amnestic MCI by Different AMYLOID/TAU Pathology. Alzheimer's and Dementia, 2016, 12, P229.	0.4	0
290	O2â€05â€02: Dementia Prevalence and Incidence in a Combination of European Electronic Health Records Databases: the EMIFâ€ad EHR Resource. Alzheimer's and Dementia, 2016, 12, P232.	0.4	0
291	O3â€05â€02: Relation Between Lifestyle Factors and Alzheimer's Disease Biomarkers in Subjects with SCI or MCI. Alzheimer's and Dementia, 2016, 12, P294.	0.4	0
292	O3-09-02: Cognitive Consequences of Cerebral Amyloid Pathology in Persons without Dementia. , 2016, 12, P307-P308.		0
293	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.4	0
294	P1â€238: When Less is More: Detecting Functional Decline Using a Short Version of the Amsterdam Iadl Questionnaire. Alzheimer's and Dementia, 2016, 12, P498.	0.4	0
295	DTâ€01â€04: Effects of Fortasyn Connect (Souvenaid) on Longitudinal Brain Atrophy Measures in Prodromal Alzheimer's Disease: Results of the Doubleâ€Blind Randomised Controlled Lipididiet Trial. Alzheimer's and Dementia, 2016, 12, P1135.	0.4	2
296	P4â€350: Biomarkers of Short Term Disease Progression in Mild Cognitive Impairment Patients with ad Pathology. Alzheimer's and Dementia, 2016, 12, P1171.	0.4	0
297	The Diagnostic and Prognostic Value ofÂNeuropsychological Assessment inÂMemory Clinic Patients. Journal of Alzheimer's Disease, 2016, 55, 679-689.	1.2	20
298	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	1.5	80
299	Impact of APOE-ɛ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging, 2016, 38, 14-20.	1.5	37
300	Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2016, 252, 26-35.	0.9	20
301	ICâ€Pâ€039: Impairment of Restingâ€State Functional Connectivity in The Defaultâ€Mode Network Closely Tracks CSF Biomarkers In MCI. Alzheimer's and Dementia, 2016, 12, P34.	0.4	2
302	O4â€09â€05: Risk Factors for Cognitive Decline are Age Dependent. Alzheimer's and Dementia, 2016, 12, P356.	0.4	0
303	Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 55, 1417-1427.	1.2	16
304	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. Human Brain Mapping, 2016, 37, 2114-2132.	1.9	38
305	Suspected non-Alzheimer disease pathophysiology — concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	4.9	230
306	Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging, 2016, 37, 154-160.	1.5	51

#	Article	IF	CITATIONS
307	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.5	54
308	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. NeuroImage, 2016, 124, 442-454.	2.1	85
309	MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study. Current Alzheimer Research, 2016, 13, 1407-1413.	0.7	3
310	P2-274: Risk score profiles for prediction of dementia in the general elderly population. , 2015, 11, P596-P596.		2
311	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.		Ο
312	P4-040: Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer's disease (AD) trials: An Alzheimer's disease neuroimaging initiative (ADNI) study. , 2015, 11, P780-P781.		0
313	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		Ο
314	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0
315	Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 35-43.	1.2	52
316	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 79-92.	1.2	31
317	FTS-01-01: A european medical information framework for Alzheimer's disease (EMIF-AD). , 2015, 11, P120-P121.		1
318	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.		0
319	The Effect of Psychological Distress and Personality Traits on Cognitive Performances and the Risk of Dementia in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 46, 805-812.	1.2	17
320	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite <scp>E</scp> uropean 3T study on healthy elderly. Human Brain Mapping, 2015, 36, 3516-3527.	1.9	34
321	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.	0.7	22
322	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
323	Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. PLoS ONE, 2015, 10, e0136181.	1.1	129
324	Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform. Alzheimer's and Dementia, 2015, 11, 1121-1122.	0.4	15

#	Article	IF	CITATIONS
325	O1-03-06: Creating normative values for cognitive tests in amyloid positive and amyloid negative cognitively normal subjects. , 2015, 11, P131-P132.		Ο
326	IC-P-108: Impact of ApoE-Æ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P73-P73.		0
327	P1-011: Prevalence of amyloid and neurodegeneration markers and effects on cognitive functioning in non-demented subjects. , 2015, 11, P340-P341.		0
328	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
329	P2-188: Characterization of cognitive function with the cantab in individuals with amnestic mild cognitive impairment in relation to hippocampal volume, amyloid, and tau status: Preliminary baseline results from the PharmaCog/european-ADNI study. , 2015, 11, P564-P564.		2
330	O2-09-01: Impact of ApoE-É>4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P194-P194.		0
331	F3-02-03: Prevalence of snap in subjects with mild cognitive impairment and dementia. , 2015, 11, P213-P214.		Ο
332	O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands. , 2015, 11, P244-P245.		0
333	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.		Ο
334	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	1.5	27
335	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 511-522.	0.4	55
336	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	3.7	284
337	Biomarkers for Alzheimer's disease: a controversial topic. Lancet Neurology, The, 2015, 14, 781-783.	4.9	8
338	The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychological Medicine, 2015, 45, 1509-1519.	2.7	39
339	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. Epigenomics, 2015, 7, 533-537.	1.0	23
340	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
341	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
342	Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk—Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1177.	3.8	6

#	Article	IF	CITATIONS
343	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	4.9	144
344	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.4	56
345	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. PLoS ONE, 2014, 9, e100784.	1.1	72
346	Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. NeuroImage, 2014, 92, 169-181.	2.1	117
347	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.4	1,863
348	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	4.9	2,657
349	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. Alzheimer's and Dementia, 2014, 10, 456-467.	0.4	16
350	The cerebrospinal fluid "Alzheimer profile― Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
351	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	1.2	307
352	IC-P-224: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS. , 2014, 10, P120-P121.		0
353	O2-05-03: USE OF CSF AMYLOID FOR DETECTING CORTICAL AMYLOID DEPOSITION: A MULTICENTER STUDY. , 2014, 10, P173-P173.		0
354	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurology, The, 2013, 12, 957-965.	4.9	471
355	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiology of Aging, 2013, 34, 2003-2013.	1.5	86
356	S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.		0
357	O3-08-01: The prevalence of amyloid pathology in healthy individuals and individuals with mild cognitive impairment: A meta-analysis of amyloid-PET studies. , 2013, 9, P533-P533.		1
358	Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer's and Dementia, 2013, 9, 481-487.	0.4	164
359	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology, 2013, 80, 1124-1132.	1.5	110
360	The Association Between APOE ε4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	1.2	7

#	Article	IF	CITATIONS
361	Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology, 2013, 81, 1409-1416.	1.5	122
362	Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dementia and Geriatric Cognitive Disorders, 2013, 36, 1-19.	0.7	41
363	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological Medicine, 2013, 43, 911-920.	2.7	93
364	Progression to dementia in memory clinic patients without dementia. Neurology, 2013, 81, 1342-1349.	1.5	21
365	Genetic Loci Associated with Alzheimer's Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort. PLoS ONE, 2013, 8, e59676.	1.1	61
366	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology, 2012, 79, 1809-1816.	1.5	129
367	Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment. Biomarkers in Medicine, 2012, 6, 365-368.	0.6	19
368	Increased risk of mortality associated with social isolation in older men: only when feeling lonely? Results from the Amsterdam Study of the Elderly (AMSTEL). Psychological Medicine, 2012, 42, 843-853.	2.7	186
369	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 319-327.	1.2	73
370	New MRI Markers for Alzheimer's Disease: A Meta-Analysis of Diffusion Tensor Imaging and a Comparison with Medial Temporal Lobe Measurements. Journal of Alzheimer's Disease, 2012, 29, 405-429.	1.2	125
371	Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 2012, 78, 468-476.	1.5	154
372	Comparison of International Working Group criteria and National Institute on Aging–Alzheimer's Association criteria for Alzheimer'sÂdisease. Alzheimer's and Dementia, 2012, 8, 560-563.	0.4	47
373	The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of Aging, 2012, 33, 201.e1-201.e8.	1.5	48
374	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging, 2012, 33, 2272-2281.	1.5	75
375	Relationship between genetic risk factors and markers for Alzheimer's disease pathology. Biomarkers in Medicine, 2012, 6, 477-495.	0.6	25
376	Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. BMC Neurology, 2012, 12, 72.	0.8	24
377	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	0.6	280
378	Fluid biomarkers for Alzheimer's disease: standardization and recent developments. Biomarkers in Medicine, 2012, 6, 363-364.	0.6	1

#	Article	IF	CITATIONS
379	Do Instrumental Activities of Daily Living Predict Dementia at 1―and 2‥ear Followâ€Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia <scp>A</scp> lzheimer's Disease Study. Journal of the American Geriatrics Society, 2011, 59, 2273-2281.	1.3	59
380	Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer's disease. Brain Structure and Function, 2011, 215, 265-271.	1.2	126
381	Predictive value of APOE-Â4 allele for progression from MCI to AD-type dementia: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1149-1156.	0.9	136
382	Regional Differences in Effects of <i>APOE</i> Îμ4 on Cognitive Impairment in Non-Demented Subjects. Dementia and Geriatric Cognitive Disorders, 2011, 32, 135-142.	0.7	18
383	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 353-366.	1.4	140
384	Consensus statement on dementia education and training in Europe. Journal of Nutrition, Health and Aging, 2010, 14, 131-135.	1.5	31
385	The Effect of the APOE-ε4 Allele and ACE-I/D Polymorphism on Cognition during a Two-Year Follow-Up in First-Ever Stroke Patients. Dementia and Geriatric Cognitive Disorders, 2010, 29, 534-542.	0.7	14
386	CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer's Disease Consortium (EADC). Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 124-125.	0.9	8
387	Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. Psychological Medicine, 2010, 40, 1193-1201.	2.7	61
388	The Predictive Value of Memory Strategies for Alzheimer's Disease in Subjects with Mild Cognitive Impairment. Archives of Clinical Neuropsychology, 2010, 25, 71-77.	0.3	10
389	Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design. Journal of Alzheimer's Disease, 2010, 20, 881-891.	1.2	130
390	Epigenetic regulation in the pathophysiology of Alzheimer's disease. Progress in Neurobiology, 2010, 90, 498-510.	2.8	237
391	Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiology of Aging, 2010, 31, 1787-1798.	1.5	97
392	Can novel therapeutics halt the amyloid cascade?. Alzheimer's Research and Therapy, 2010, 2, 5.	3.0	19
393	White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1069-1074.	0.9	39
394	Predictive Value of Mild Cognitive Impairment for Dementia. Dementia and Geriatric Cognitive Disorders, 2009, 27, 173-181.	0.7	65
395	Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI. Neurology, 2009, 73, 744-745.	1.5	13
396	Characteristics of helpâ€seeking behaviour in subjects with subjective memory complaints at a memory clinic: a caseâ€control study. International Journal of Geriatric Psychiatry, 2009, 24, 190-196.	1.3	63

#	Article	IF	CITATIONS
397	Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment. Journal of Nutrition, Health and Aging, 2009, 13, 344-345.	1.5	4
398	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
399	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, The, 2009, 8, 619-627.	4.9	542
400	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	1.2	42
401	Brain SPECT in subtypes of mild cognitive impairment. Journal of Neurology, 2008, 255, 1344-1353.	1.8	54
402	The Association between APOE Genotype and Memory Dysfunction in Subjects with Mild Cognitive Impairment Is Related to Age and Alzheimer Pathology. Dementia and Geriatric Cognitive Disorders, 2008, 26, 101-108.	0.7	58
403	Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer's Disease. Neuroepidemiology, 2008, 30, 254-265.	1.1	86
404	Mild cognitive impairment as predictor for Alzheimer's disease in clinical practice: effect of age and diagnostic criteria. Psychological Medicine, 2008, 38, 113-122.	2.7	50
405	The ICTUS Study: A Prospective Longitudinal Observational Study of 1,380 AD Patients in Europe. Neuroepidemiology, 2007, 29, 29-38.	1.1	51
406	Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology, 2007, 68, 1238-1239.	1.5	1
407	Symptoms of Preclinical Dementia in General Practice up to Five Years before Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders, 2007, 24, 300-306.	0.7	47
408	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	4.9	3,755
409	Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?. , 2006, 2, 220-233.		25
410	Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 714-718.	0.9	539
411	MILD COGNITIVE IMPAIRMENT SUBTYPES AND VASCULAR DEMENTIA. Journal of the American Geriatrics Society, 2006, 54, 1966-1967.	1.3	5
412	Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology, 2006, 67, 1201-1207.	1.5	191
413	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 439-442.	0.9	165
414	Role of cognitive testing in disease modifying AD trials. Journal of Nutrition, Health and Aging, 2006, 10, 131-2; discussion 132-3.	1.5	8

#	Article	IF	CITATIONS
415	MCI is not a clinically useful concept. International Psychogeriatrics, 2006, 18, 402-9; discussion 409-14.	0.6	20
416	Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimer's Disease Patients. Dementia and Geriatric Cognitive Disorders, 2005, 19, 126-133.	0.7	28
417	Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1348-1354.	0.9	107
418	Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase, 2005, 11, 8-13.	0.2	47
419	Predictive Accuracy of MCI Subtypes for Alzheimer's Disease and Vascular Dementia in Subjects with Mild Cognitive Impairment: A 2-Year Follow-Up Study. Dementia and Geriatric Cognitive Disorders, 2005, 19, 113-119.	0.7	162
420	Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology, 2004, 63, 94-100.	1.5	307
421	Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine, 2004, 256, 240-246.	2.7	4,039
422	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. NeuroImage, 2004, 23, 708-716.	2.1	522
423	Characteristics of preclinical Alzheimer's disease. International Journal of Geriatric Psychiatry, 2002, 17, 88-89.	1.3	8
424	Course of minimal dementia and predictors of outcome. International Journal of Geriatric Psychiatry, 2002, 17, 835-841.	1.3	15
425	Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. Journal of Neurology, 2002, 249, 312-319.	1.8	51
426	Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 491-7.	0.9	259
427	Thalamic volume predicts performance on tests of cognitive speed and decreases in healthy aging. Cognitive Brain Research, 2001, 11, 377-385.	3.3	131
428	Diagnosis of Preclinical Alzheimer's Disease in a Clinical Setting. International Psychogeriatrics, 2001, 13, 411-423.	0.6	31
429	Normal Cognitive Performance in Patients With Chronic Alcoholism in Contrast to Patients With Korsakoff's Syndrome. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 44-50.	0.9	34
430	Phenomenology of Depression in Dementia. International Psychogeriatrics, 2000, 12, 129-134.	0.6	6
431	Distinction Between Preclinical Alzheimer's Disease and Depression. Journal of the American Geriatrics Society, 2000, 48, 479-484.	1.3	108
432	Course of objective memory impairment in non-demented subjects attending a memory clinic and predictors of outcome. International Journal of Geriatric Psychiatry, 2000, 15, 363-372.	1.3	45

#	Article	IF	CITATIONS
433	The relation between global and limbic brain volumes on MRI and cognitive performance in healthy individuals across the age range. Neurobiology of Aging, 2000, 21, 569-576.	1.5	123
434	Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. Journal of Neurology, 1999, 246, 477-485.	1.8	298
435	Brain correlates of memory dysfunction in alcoholic Korsakoff's syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 774-778.	0.9	71
436	Magnesium therapy in acute myocardial infarction. Netherlands Journal of Medicine, 1995, 46, 156-165.	0.6	3
437	Mild Cognitive Impairment. , 0, , 1095-1101.		4
438	<i>APOE</i> -ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting. The Cochrane Library, 0, , .	1.5	4
439	<i>APOE</i> -ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting. The Cochrane Library, 0, , .	1.5	4
440	<i>APOE</i> -ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting. The Cochrane Library, 0, , .	1.5	4